Garcha G, Smokcum R W, Stephenson J D, Weeramanthri T B
Eur J Pharmacol. 1985 Jan 15;108(1):1-7. doi: 10.1016/0014-2999(85)90276-6.
The effects of daily administration to rats of desipramine, talsupram, tomoxetine, maprotiline, nomifensine, mianserin and citalopram (each 10 mg kg-1 day-1) for 4 weeks on [3H]dihydroalprenolol ([3H]DHA) binding in the cerebral cortex and on the noradrenaline-sensitive adenylate cyclase in the limbic forebrain were determined. Of these compounds, desipramine was alone in reducing [3H]DHA binding and in attenuating the cAMP response. Two selective noradrenaline uptake inhibitors, talsupram and tomoxetine each reduced the cAMP response but without affecting [3H]DHA binding. The other drugs lacked effect on both measures indicating (except for citalopram) that reduction in sensitivity of beta-adrenoceptors and of the noradrenaline-sensitive cAMP response might not be a simple consequence of noradrenaline uptake inhibition. The lack of effect of citalopram on the sensitivity of the beta-adrenoceptor system suggests that antidepressants with selective 5-HT uptake inhibitory properties owe their antidepressant activity to other mechanisms.
测定了将地昔帕明、他索普明、托莫西汀、马普替林、诺米芬辛、米安色林和西酞普兰(均为10毫克/千克/天)每日给大鼠服用4周对大脑皮质中[3H]二氢烯丙洛尔([3H]DHA)结合以及对边缘前脑去甲肾上腺素敏感腺苷酸环化酶的影响。在这些化合物中,只有地昔帕明能降低[3H]DHA结合并减弱环磷酸腺苷(cAMP)反应。两种选择性去甲肾上腺素摄取抑制剂,他索普明和托莫西汀各自都能降低cAMP反应,但不影响[3H]DHA结合。其他药物对这两种指标均无影响,这表明(西酞普兰除外)β-肾上腺素能受体敏感性降低以及去甲肾上腺素敏感的cAMP反应降低可能并非去甲肾上腺素摄取抑制的简单结果。西酞普兰对β-肾上腺素能受体系统敏感性无影响,这表明具有选择性5-羟色胺摄取抑制特性的抗抑郁药的抗抑郁活性归因于其他机制。